Carlyle Group’s Vaxcyte PCVX Stock Holding History

Carlyle Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,923,158	Closed	-$72.1M	–	27
2023 Q1	$72.1M	Buy	+1,923,158	New	+$81.6M	2.15%	6

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Carlyle Group's PCVX Position: Q2 2023 in Review

Carlyle Group sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 1,923,158 shares — an estimated $72.1M sold.

Carlyle Group first reported a position in PCVX in Q1 2023 and held it in 1 quarter. The position peaked at $72.1M in Q1 2023. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

Carlyle Group reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
Carlyle Group sold 1,923,158 Vaxcyte shares in Q2 2023, an estimated $72.1M.
Carlyle Group first reported a position in Vaxcyte in Q1 2023 and held it in 1 quarter.
Carlyle Group's Vaxcyte position peaked at $72.1M in Q1 2023.
197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Carlyle Group's 13F filing for Q2 2023, filed 4 Aug 2023.